Obstetrical management of patients at risk of neonatal lupus syndrome: Review of the literature;Prise en charge obstétricale des patientes à risque de «lupus néonatal»: Revue de la littérature

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 35, Issue 2, 2006, Pages 146-156

  Costedoat Chalumeau, N ^a   Amoura, Z ^a   Villain, E ^b   Cohen, L ^c   Fermont, L ^d   Le Thi Huong, D ^a   Vauthier, D ^a   Georgin Lavialle, S ^a   Wechsler, B ^a   Dommergues, M ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Institut Jacques Cartier   (France)

^d Institut de Puericulture   (France)

Author keywords

Anti SSA Ro antibodies; Anti SSB La antibodies; Congenital heart block; Gougerot Sj gren; Neonatal lupus erythematosus; Systemic lupus erythematosus

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; FLUORINATED STEROID; LA ANTIBODY; PREDNISOLONE; PREDNISONE; RO ANTIBODY; ANTINUCLEAR ANTIBODY; SS A ANTIBODIES; SS B ANTIBODIES; SS-A ANTIBODIES; SS-B ANTIBODIES;

CARDIOMYOPATHY; CLINICAL FEATURE; CONGENITAL HEART BLOCK; CONGENITAL HEART MALFORMATION; CONNECTIVE TISSUE DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOCARDIAL FIBROELASTOSIS; GESTATION PERIOD; HEMATOLOGIC DISEASE; HUMAN; IMPLANT; LIVER DISEASE; LUPUS ERYTHEMATOSUS; MEDICAL LITERATURE; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NEWBORN DISEASE; NEWBORN LUPUS ERYTHEMATOSUS; PREGNANCY; REVIEW; RISK ASSESSMENT; SINUS NODE; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASE; BLOOD; FEMALE; IMMUNOLOGY; MALE; NEWBORN; PREGNANCY COMPLICATION; SKIN DISEASE; SYNDROME;

ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; FEMALE; HEART DEFECTS, CONGENITAL; HEMATOLOGIC DISEASES; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LIVER DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; SKIN DISEASES; SYNDROME;

EID: 33646688198     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(06)76388-8     Document Type: Review

References (67)

1. Buyon JP. Autoantibodies reactive with Ro(SSA) and La(SSB) and pregnancy. J Rheumatol 1997; 24: 12-6.
2. Buyon JP. Neonatal lupus syndromes. Curr Opin Rheumatol 1994; 6: 523-9.
3. Buyon JP. Neonatal lupus: bedside to bench and back. Scand J Rheumatol 1996; 25: 271-6.
4. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120: 544-51.
5. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-66.
6. Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137: 674-80.
7. Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics 2002; 109: E11.
8. Press J, Uziel Y, Laxer RM, Luy L, Hamilton RM, Silverman ED. Long-term outcome of mothers of children with complete congenital heart block. Am J Med 1996; 100: 328-32.
9. Lawrence S, Luy L, Laxer R, Krafchik B, Silverman E. The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block. Am J Med 2000; 108: 705-9.
10. Brucato A, Gasparini M, Vignati G, Riccobono S, De Juli E, Quinzanini M et al. Isolated congenital complete heart block: longterm outcome of children and immunogenetic study. J Rheumatol 1995; 22: 541-3.
11. Brucato A, Franceschini F, Gasparini M, De Juli E, Ferraro G, Quinzanini M et al. Isolated congenital complete heart block: longterm outcome of mothers, maternal antibody specificity and immunogenetic background. J Rheumatol 1995; 22: 533-40.
12. Brucato A, Franceschini F, Buyon JP. Neonatal lupus: long-term outcomes of mothers and children and recurrence rate. Clin Exp Rheumatol 1997; 15: 467-73.
13. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum 2001; 44: 487-8.
14. Julkunen H, Eronen M. Long-term outcome of mothers of children with isolated heart block in Finland. Arthritis Rheum 2001; 44: 647-52.
15. Eronen M, Siren MK, Ekblad H, Tikanoja T, Julkunen H, Paavilainen T. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000; 106: 86-91.
16. De Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993; 11: 393-7.
17. Meyer O, Kahn MF. Lupus érythémateux systémique. Paris: Flammarion-Médecine Sciences, 2000, p. 131-368bis.
18. Michaelsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4: 85-101.
19. Siren MK, Julkunen H, Kaaja R. The increasing incidence of isolated congenital heart block in Finland. J Rheumatol 1998; 25: 1862-4.
20. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-5.
21. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Le Thi Huong D, Denjoy I, Vauthier D, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50: 3187-94.
22. Cooley HM, Keech CL, Melny BJ, Menahem S, Morahan G, Kay TW. Monozygotic twins discordant for congenital complete heart block. Arthritis Rheum 1997; 40: 381-4.
23. Buyon JP, Clancy RM. Autoantibody-associated congenital heart block: TGFbeta and the road to scar. Autoimmun Rev 2005; 4: 1-7.
24. Clancy RM, Backer CB, Yin X, Kapur RP, Molad Y, Buyon JP. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 2003; 171: 3253-61.
25. Buyon JP, Winchester RJ, Slade SG, Arnett F, Copel J, Friedman D et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36: 1263-73.
26. Julkunen H, Kaaja R, Siren MK, Mack C, McCready S, Holthofer H et al. Immune-mediated congenital heart block (CHB): identifying and counseling patients at risk for having children with CHB. Semin Arthritis Rheum 1998; 28: 97-106.
27. Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 1233-41.
28. Gordon P, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31: 2480-7.
29. Gordon PA, Rosenthal E, Khamashta MA, Hughes GR. Absence of conduction defects in the electrocardiograms of mothers with children with congenital complete heart block. J Rheumatol 2001; 28: 366-9.
30. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Ghillani P, Lechat P, Funck-Brentano C et al. Corrected QT interval in anti-SSA-positive adults with connective tissue disease: comment on the article by Lazzerini et al. Arthritis Rheum 2005; 52: 676-8.
31. Herreman G, Galezewski N. Maternal connective tissue disease and congenital heart block. N Engl J Med 1985; 312: 1329.
32. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42: 2335-45.
33. Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol 1991; 17: 1360-6.
34. Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110: 1542-8.
35. Hogg GR. Congenital, acute lupus erythematosus associated with subendocardial fibroelastosis. Report of a case. Am J Clin Pathol 1957; 28: 648-54.
36. Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JB, Silverman NH et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105: 843-8.
37. Nield LE, Silverman ED, Smallhorn JF, Taylor GP, Mullen JB, Benson LN et al. Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40: 796-802.
38. Raboisson MJ, Fouron JC, Sonesson SE, Nyman M, Proulx F, Gamache S. Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. J Am Soc Echocardiogr 2005; 18: 375-80.
39. Costedoat-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC. Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther 2005; 7: 69-73.
40. Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37: 238-42.
41. Villain E, Marijon E, Georgin S. Is isolated congenital heart block with maternal antibodies a distinct and more severe form of the disease in childhood? (abstract). Heart Rhythm 2005; 2: S45.
42. Udink ten Cate FE, Breur JM, Cohen MI, Boramanand N, Kapusta L, Crosson JE et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37: 1129-34.
43. Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11: 145-51.
44. Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86: 236-9.
45. Glickstein J, Buyon J, Kim M, Friedman D. The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther 2004; 19: 31-4.
46. Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253-61.
47. Friedman D, Buyon J, Copel J, Kim M. PR interval and dexamethasone evaluation: an ongoing prospective fetal echocardiographic study in neonatal lupus. I - observational (abstract). Lupus 2004; 13: 760.
48. Buyon JP, Rupel A, Clancy RM. Neonatal lupus syndromes. Lupus 2004; 13: 705-12.
49. Buyon JP, Askanase AD, Kim MY, Copel JA, Friedman DM. Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum 2005; 52: 1341-2.
50. Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, Georgin S, Vauthier D, Sebbouh D et al. «Lupus néonatal» : revue de la littérature. Rev Med Interne 2003; 24: 659-71.
51. Prendiville JS, Cabral DA, Poskitt KJ, Au S, Sargent MA. Central nervous system involvement in neonatal lupus erythematosus. Pediatr Dermatol 2003; 20: 60-7.
52. Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46: 2377-83.
53. Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999; 93: 952-7.
54. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127: 264-7.
55. Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, Wechsler B, Vauthier D, Ghillani P et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62 :1010-2.
56. Chico A, Manzanares JM, Halperin I, Martinez de Osaba MJ, Adelantado J, Webb SM. Cushing's disease and pregnancy: report of six cases. Eur J Obstet Gynecol Reprod Biol 1996; 64: 143-6.
57. Uno H, Lohmiller L, Thieme C, Kemnitz JW, Engle MJ, Roecker EB et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res 1990; 53: 157-67.
58. Miller WL. Dexamethasone treatment of congenital adrenal hyperplasia in utero: an experimental therapy of unproven safety. J Urol 1999; 162: 537-40.
59. Lajic S, Nordenstrom A, Ritzen EM, Wedell A. Prenatal treatment of congenital adrenal hyperplasia. Eur J Endocrinol 2004; 151 (suppl. 3): U63-9.
60. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1: 1.
61. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341: 1190-6.
62. Spinillo A, Viazzo F, Colleoni R, Chiara A, Maria Cerbo R, Fazzi E. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191: 217-24.
63. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001; 50: 706-11.
64. Buyon JP, Swersky SH, Fox HE, Bierman FZ, Winchester RJ. Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Experience in a mother with a predominance of SS-B (La) antibodies. Arthritis Rheum 1987; 30: 44-9.
65. Jaeggi ET, Silverman ED, Yoo SJ, Kingdom J. Is immunemediated complete fetal atrioventricular block reversible by transplacental dexamethasone therapy? Ultrasound Obstet Gynecol 2004; 23: 602-5.
66. Rosenthal E, Gordon PA, Simpson JM, Sharland GK. Letter regarding article by Jaeggi et al, "transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease". Circulation 2005; 111: e287-8.
67. Vesel S, Mazic U, Blejec T, Podnar T. First-degree heart block in the fetus of an anti-SSA/Ro-positive mother: reversal after a short course of dexamethasone treatment. Arthritis Rheum 2004; 50: 2223-6.